The 50 Insider
-
HSBC chooses Featurespace technology
Featurespace’s fraudbusting technology has been chosen by HSBC to support efforts to strengthen anti-money laundering and fraud efforts in the... Read More
-
Speechmatics adds grammar glamour to voice revolution
Speechmatics, the Cambridge-UK leader in machine learning and automatic speech recognition, has added grammar glamour to its technology offering.... Read More
-
High lands in the stream as Bango and Spotify join forces
Cambridge mobile technology company Bango has joined forces with Swedish streaming world-leader Spotify in a game-changing alliance. The companies... Read More
-
Trust in Rust as 42T boosts IoT technology
Cambridge cluster product innovator 42 Technology has launched the world’s first Rust programming language application for a single-chip Internet of... Read More
-
New era for Acacia as Bolinder takes over from Gilbert as CEO
Cambridge-based Acacia Pharma Group plc has changed CEO as it gears up for major growth in the United States. Company founder Julian Gilbert has... Read More
-
CRFS ramps technology for military bases and test ranges
Global military players – notably in the US – have been alerted to a new technology proposition launched by Cambridge-based CRFS, a global leader in... Read More
-
Bicycle Therapeutics revamps board to oversee fresh growth spurt
Bicycle Therapeutics plc, which is pioneering a new class of therapeutics based on its proprietary bicyclic peptide technology, has unveiled key... Read More
-
Isomerase scaling at Chesterford Research Park
Isomerase has secured the first pre-let within the Newnham Building at Chesterford Research Park. The move to Suite 4 of the new building on its... Read More
-
GE Healthcare CTO joins PhoreMost board
PhoreMost, a Cambridge biopharma company dedicated to drugging ‘undruggable’ disease targets, has appointed Dr Lorenz Mayr to its board as a non-... Read More
-
Blighter prepped for further expansion with new board
Cambridge radar firm Blighter has unveiled a new board to build on record sales through geographic expansion and continued focus on defence &... Read More
-
French connection boosts Inivata lung cancer trial
Inivata, a Cambridge-based leader in liquid biopsy, and the Centre Léon Bérard cancer centre in Lyon, France, have started a randomised phase III... Read More
-
Bicycle Therapeutics firmly in the Nasdaq saddle after $60.6m IPO
Cambridge cancer drug innovator Bicycle Therapeutics, which raised $60.6 million on its Nasdaq IPO in the US, has settled nicely on the American... Read More
-
Featurespace digital onboarding solution tightens net on online fraudsters
Cambridge fraud-busting innovator Featurespace has launched Adaptive Behavioural Biometrics which uses in-session behavioural data collected from... Read More
-
Crescendo Biologics earns Takeda payout
Cambridge life science company Crescendo Biologics has achieved a fourth milestone in its collaboration with Takeda Pharmaceutical Company. The... Read More
-
Cambridge software proves arresting proposition for US police
Pioneering in-vehicle technology from Cambridge company VNC Automotive is being used in America to help first responders answer emergency callouts... Read More
-
Cambridge Intelligence launches ReGraph for React developers
Cambridge Intelligence has launched an early access program for ReGraph, a new graph data visualisation toolkit. ReGraph is a React toolkit for... Read More
-
Summers a man with a Mission
Mission Therapeutics in Cambridge, whose technology promises cures for Alzheimer’s and Parkinson’s diseases, has added fresh muscle to its board with... Read More
-
Global double whammy for fast-growing Arecor
A global top 20 pharmaceutical giant is leveraging proprietary formulation technology from Arecor, the Chesterford Research Park-based company.... Read More
-
NodThera advances lead candidate and adds two big hitters to board
NodThera, a Cambridge biotech company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, has... Read More
-
Domainex helping to develop potential new heart drug
Domainex scientists in Cambridge, working with Professor Michael Schneider and his team at Imperial College, have found a potential new drug for... Read More